Publication:
Free Text: Efficacy of different nitric oxide-based strategies in preventing experimental cerebral malaria by Plasmodium berghei ANKA.


abstract

BACKGROUND:

Low nitric oxide (NO) bioavailability plays a role in the pathogenesis of human as well as of experimental cerebral malaria (ECM) caused by Plasmodium berghei ANKA (PbA). ECM is partially prevented by administration of the NO-donor dipropylenetriamine NONOate (DPTA-NO) at high concentration (1 mg/mouse), which also induces major side effects such as a sharp drop in blood pressure. We asked whether alternative strategies to improve NO bioavailability with minor side effects would also be effective in preventing ECM.

METHODOLOGY/PRINCIPAL FINDINGS:

Mice were infected with PbA and prophylactically treated twice a day with bolus injections of L-arginine, Nω-hydroxy-nor-Arginine (nor-NOHA), tetrahydrobiopterin (BH4), separately or combined, sodium nitrite, sildenafil or sildenafil plus DPTA-NO starting on day 0 of infection. L-arginine and BH4 supplementation, with or without arginase inhibition by nor-NOHA, increased plasma nitrite levels but failed to protect against ECM development. Accordingly, prophylactic treatment with continuous delivery of L-arginine using osmotic pumps also did not improve survival. Similar outcomes were observed with sodium nitrite sildenafil (aimed at inhibiting phosphodiesterase-5) or with DPTA-NO. However, sildenafil (0.1 mg/mouse) in combination with a lower dose (0.1 mg/mouse) of DPTA-NO decreased ECM incidence (82 ± 7.4% mortality in the saline group and 38 ± 10.6% in the treated group; p<0.05). The combined prophylactic therapy did not aggravate anemia, had delayed effects in systolic, diastolic and mean arterial blood pressure and induced lower effects in pulse pressure when compared to DPTA-NO 1 mg/mouse.

CONCLUSIONS/SIGNIFICANCE:

These data show that sildenafil lowers the amount of NO-donor needed to prevent ECM, resulting also in lesser side effects. Prophylactic L-arginine when given in bolus or continuous delivery and bolus BH4 supplementation, with or without arginase inhibition, were able to increase NO bioavailability in PbA-infected mice but failed to decrease ECM incidence in the doses and protocol used.

Related Articles
S-nitrosoglutathione Prevents Experimental Cerebral Malaria.
J Neuroimmune Pharmacol. 2012
S-nitrosoglutathione Prevents Experimental Cerebral Malaria.
Zanini GM, Martins YC, Cabrales P, Frangos JA, Carvalho LJ. J Neuroimmune Pharmacol. 2012 Jun; 7(2):477-87. Epub 2012 Mar 6.
Exogenous nitric oxide decreases brain vascular inflammation, leakage and venular resistance during Plasmodium berghei ANKA infection in mice.
J Neuroinflammation. 2011
Exogenous nitric oxide decreases brain vascular inflammation, leakage and venular resistance during Plasmodium berghei ANKA infection in mice.
Zanini GM, Cabrales P, Barkho W, Frangos JA, Carvalho LJ. J Neuroinflammation. 2011 Jun 7; 8:66. Epub 2011 Jun 7.
Final Report on Carcinogens Background Document for Styrene.
Rep Carcinog Backgr Doc. 2008
Final Report on Carcinogens Background Document for Styrene.
National Toxicology Program. Rep Carcinog Backgr Doc. 2008 Sep; (8-5978):i-398.
Review 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Dan Med Bull. 2008
Review 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L. Dan Med Bull. 2008 Nov; 55(4):186-210.
Review [Nitric oxide and anti-protozoan chemotherapy].
Parassitologia. 2004
Review [Nitric oxide and anti-protozoan chemotherapy].
Gradoni L, Ascenzi P. Parassitologia. 2004 Jun; 46(1-2):101-3.